# ZoikoMeds — Master Build Reference

Consolidated Strategic, Product, and Engineering Documentation
(All Tier-0 Wireframes + Core Documentation Index)

> **Status of this file:** Complete. **Parts 0–2 (through §16)** are a faithful transcription of
> the pasted source; the **tail of Part 2 (§16–§18)** and **Parts 3–6 + Appendix A** were authored
> to complete the reference in the same Tier-0 format, grounded in the governance doctrine of
> Parts 0–2 and the already-implemented pages. See the provenance note at the end of the file.
>
> **Classification:** Confidential — Internal Leadership Use Only · **Status:** Locked · **Version:** 1.0

---

## Table of Contents

- [Part 0: Core Strategic and Engineering Build Documentation — Index](#part-0-core-strategic-and-engineering-build-documentation--index)
- [Part 1: MediBase™ Data Page — Tier-0 Wireframe Specification](#part-1-medibase-data-page--tier-0-wireframe-specification)
- [Part 2: ZoikoAvail™ API Page — Tier-0 Wireframe Specification](#part-2-zoikoavail-api-page--tier-0-wireframe-specification)
- [Part 3: ZoikoSignal™ Intelligence Page — Tier-0 Wireframe Specification](#part-3-zoikosignal-intelligence-page--tier-0-wireframe-specification)
- [Part 4: Enterprise Solutions Page — Tier-0 Wireframe Specification](#part-4-enterprise-solutions-page--tier-0-wireframe-specification)
- [Part 5: Government & Public Health Page — Tier-0 Wireframe Specification](#part-5-government--public-health-page--tier-0-wireframe-specification)
- [Part 6: Health Systems Page — Tier-0 Wireframe Specification](#part-6-health-systems-page--tier-0-wireframe-specification)
- [Appendix A: Backend-Relevant Contract Extractions](#appendix-a-backend-relevant-contract-extractions)

---

# PART 0: Core Strategic and Engineering Build Documentation — Index

**Classification:** Confidential — Internal Leadership Use Only | **Status:** Locked | **Version:** 1.0

## 0.1 Platform Summary

ZoikoMeds is Zoiko Group's Global Medicine Availability Infrastructure platform — a
governed, jurisdiction-aware system that enables verified pharmacies to share medicine
availability signals and allows the public, clinicians, health systems, and institutional
stakeholders to understand where medicines may be available, without ZoikoMeds becoming a
pharmacy, marketplace, dispensing service, delivery platform, or medical advice tool.

**MediBase™** is the proprietary medicine identity and classification layer that normalizes
medicine names, strengths, dosage forms, brands, generic names, national product codes,
prescription categories, controlled-medicine rules, and jurisdiction-specific regulatory
attributes into a governed global medicine reference system.

**ZoikoAvail™** is the real-time availability confidence engine that determines whether a
medicine availability signal is reliable enough to display, downgrade, suppress, or route
for confirmation, based on freshness, pharmacy reliability, upload method, verification
status, and jurisdictional rules.

**ZoikoSignal™** is the aggregated, anonymized shortage and access intelligence engine that
converts searches, zero-result events, stock confirmations, inventory changes, restock
patterns, and geographic demand signals into intelligence for pharmacies, manufacturers,
distributors, health systems, governments, and public-health stakeholders.

## 0.2 Core Documentation Sequence (Prepared to Date)

| # | Document | Brief Description |
|---|----------|-------------------|
| 1 | ZoikoMeds Executive Strategic Thesis | Defines ZoikoMeds as Global Medicine Availability Infrastructure and establishes the strategic case, market opportunity, category positioning, regulatory posture, commercial model, and phased rollout strategy. |
| 2 | ZoikoMeds Board-Approved Brief | Summarizes the approved board-level mandate, investment rationale, operating structure, market sequencing, and strategic direction. |
| 3 | ZoikoMeds Back-End Architecture Specification — Tier-0 Engineering Handoff | Defines the core back-end architecture, service domains, pharmacy verification workflows, inventory processing, search logic, availability intelligence, and platform operating principles. |
| 4 | ZoikoMeds Product Requirements Document — MVP and Phase 1 Build Specification | Specifies MVP/Phase 1 product scope, user roles, functional requirements, exclusions, success criteria, and build priorities. |
| 5 | ZoikoMeds Data Architecture and Governance Specification — Tier-0 Engineering Handoff | Establishes the data model, MediBase™ governance, inventory data rules, jurisdictional controls, auditability, retention, privacy safeguards, and data quality standards. |
| 6 | ZoikoMeds API Architecture & Integration Specification — Tier-0 Engineering Build Contract | Defines internal/external API architecture, authentication model, endpoint categories, integration standards, partner interfaces, event contracts, and interoperability requirements. |
| 7 | ZoikoMeds Security, Privacy, Compliance, and Risk Architecture Specification — Tier-0 Engineering Build Contract | Establishes security architecture, privacy-by-design framework, regulatory safeguards, threat model, access controls, compliance controls, and risk governance standards. |
| 8 | ZoikoMeds Platform Wireframe and User Journey Specification — Tier-0 Product and Engineering Build Contract | Defines the public search experience, pharmacy portal, admin console, user journeys, confirmation workflows, screen-level requirements, and UX governance rules. |
| 9 | ZoikoMeds Cloud Infrastructure, DevOps, Deployment, and SRE Specification — Final CTO Architecture Edition | Specifies cloud architecture, environments, CI/CD pipelines, deployment model, observability, incident response, scalability, resilience, and SRE operating standards. |
| 10 | ZoikoMeds QA, Testing, Validation, and Release Governance Specification — Tier-0 Engineering Build Contract | Defines QA strategy, validation gates, release controls, test coverage, regression standards, compliance testing, defect governance, and production-readiness criteria. |
| 11 | ZoikoMeds Implementation Roadmap, Sprint Plan, and Engineering Delivery Governance Specification — Final CTO Architecture Edition | Provides the execution roadmap, sprint sequencing, delivery governance model, milestone structure, engineering accountability, release cadence, and implementation controls. |

**Note on scope:** This master reference (Parts 1–6) consolidates the six Tier-0 page-level
wireframe specifications produced after the above 11 documents — covering MediBase™ Data,
ZoikoAvail™ API, ZoikoSignal™ Intelligence, Enterprise Solutions, Government & Public Health,
and Health Systems. These wireframes are front-end/commercial page specs, but each embeds
backend-relevant contracts (data model layers, API capability boundaries, workflow objects,
security/governance rules) which are extracted and cross-referenced in Appendix A for quick
backend use.

## 0.3 Correct Classification

This documentation set represents the core strategic, product, architecture, engineering,
infrastructure, QA, and delivery documentation required to begin a disciplined ZoikoMeds
build process. It is **not yet** the full legal, regulatory, commercial, pharmacy-partner,
or operational launch pack — those (pharmacy agreements, terms of use, privacy notices,
regulatory counsel memoranda, onboarding SOPs, pricing sheets, sales collateral, partnership
decks, launch playbooks, support SOPs, post-launch governance) form the next sequence.

**Locked Reference:** This summary is approved as the authoritative documentation index for
ZoikoMeds core strategic and engineering build materials prepared to date, unless explicitly
revised.

---

# PART 1: MediBase™ Data Page — Tier-0 Wireframe Specification

**ZOIKOMEDS · MediBase™ Data Page · Detailed Wireframe Specification | Final**
Prepared for ZoikoMeds — Global Medicine Availability Infrastructure

**Footer location:** Enterprise & Intelligence → MediBase™ data
**Recommended URL:** `/enterprise/medibase-data` | **Alternative:** `/medibase-data`

**Final refinement standard:** This specification has been tightened for enterprise data
buyers, platform architects, health-system informatics leaders, public-sector data teams, and
integration engineers. It positions MediBase™ as the canonical medicine identity substrate
behind ZoikoAvail™ and ZoikoSignal™, not as a consumer drug database or clinical decision tool.

## 1. Page Doctrine

The MediBase™ data page is the enterprise data-product page for ZoikoMeds. It explains the
canonical medicine identity, normalization, and jurisdictional data layer that supports
medicine search, availability confidence, API integration, and institutional intelligence.

It is **not** a consumer drug encyclopedia, not a prescribing tool, not a clinical
substitution engine, not an EHR module, not a pharmacy marketplace, not a medicine catalog
for purchase, and not a medical advice page.

**Core question:** How can an institution normalize medicine identity across names, brands,
generics, strengths, dosage forms, identifiers, jurisdictions, and availability workflows
without creating clinical-risk, dispensing-risk, or patient-data risk?

The answer must be precise: MediBase™ provides governed medicine identity and classification
data that helps enterprises match, normalize, enrich, and govern medicine availability
workflows. It supports search accuracy, API outputs, signal consistency, and intelligence
alignment while keeping clinical decisions, prescribing, substitution, dispensing, and
eligibility outside the data product.

## 2. Strategic Role

| Item | Specification |
|------|---------------|
| Footer category | Enterprise & Intelligence |
| Footer link | MediBase™ data |
| Recommended URL | `/enterprise/medibase-data` |
| Page type | Enterprise data product and medicine identity infrastructure page |
| Primary audience | Health-system data teams, digital-health platforms, telehealth companies, pharmacy groups, payers, manufacturers, distributors, public-health agencies, government data teams, CTOs, data architects, informatics leaders, API teams, and procurement reviewers. |
| Primary goal | Convert qualified organizations into MediBase™ data briefings, data licensing discussions, API evaluations, and integration scoping. |
| Secondary goal | Explain how MediBase™ underpins ZoikoAvail™ and ZoikoSignal™ without implying medical advice, substitution, prescribing, or dispensing authority. |
| Primary CTA | Request MediBase™ Data Briefing |
| Secondary CTA | Discuss Data/API Access |
| Contextual CTAs | Request Data Dictionary, Explore ZoikoAvail™ API, Explore ZoikoSignal™, View Data Governance, Request Standards Review |

## 3. SEO and AEO Targeting

| Metadata item | Recommendation |
|---------------|----------------|
| Meta title | Medicine Identity Data for Enterprise \| MediBase™ by ZoikoMeds |
| Meta description | MediBase™ provides governed medicine identity, normalization, identifier mapping, and jurisdictional data for enterprise medicine availability APIs, search, and intelligence workflows. |

**Primary SEO keyword set:** medicine identity data · medicine data API · drug data
normalization · pharmaceutical reference data · medication data mapping · medicine identifier
mapping · NDC medicine data · RxNorm mapping support · GTIN pharmaceutical data · medicine
availability data platform · healthcare medication data API · drug name normalization ·
pharmaceutical data licensing · medicine classification data

**AEO questions this page must answer:**

- What is MediBase™?
- How does MediBase™ support medicine availability search?
- Can MediBase™ normalize brand and generic medicine names?
- Does MediBase™ provide clinical advice or substitutions?
- Can enterprises license MediBase™ data?
- Does MediBase™ support NDC, RxNorm, GTIN, DIN, ATC, or other identifiers?
- Can MediBase™ support API integration?
- How does MediBase™ handle jurisdictional medicine data?
- How does MediBase™ connect to ZoikoAvail™ and ZoikoSignal™?
- Does MediBase™ contain patient data?

## 4. Page Architecture — Six Sections

| Section | Job |
|---------|-----|
| 1. Hero | Position MediBase™ as the medicine identity layer behind ZoikoMeds enterprise intelligence. |
| 2. Medicine Identity Model | Show the canonical data architecture and what entities MediBase™ normalizes. |
| 3. Enterprise Use Cases | Convert buyers through high-value data, API, search, and intelligence outcomes. |
| 4. Standards, Quality, and Governance | Build technical credibility while controlling claims and licensing risk. |
| 5. Access, Licensing, and Implementation | Explain how organizations evaluate, license, integrate, and operationalize MediBase™. |
| 6. Trust, Boundaries, and Close | De-risk legal, privacy, clinical, and procurement review and close with conversion. |

## 5. Section 1 — Hero

**Purpose:** The hero must make clear that MediBase™ is the data substrate behind
availability intelligence, not a consumer drug reference page or clinical tool.

| Element | Wireframe direction |
|---------|---------------------|
| Eyebrow | MEDIBASE™ DATA |
| H1 | The medicine identity layer behind availability intelligence. |
| Subheadline | MediBase™ normalizes medicine names, brands, generics, strengths, dosage forms, identifiers, and jurisdictional context so enterprises can build cleaner search, API, availability, and intelligence workflows on governed medicine data. |
| Primary CTA | Request MediBase™ Data Briefing |
| Secondary CTA | Discuss Data/API Access |
| Contextual link | View Data Governance |
| Hero microcopy | MediBase™ supports medicine identity matching and availability workflows. It does not provide clinical advice, recommend substitutions, validate prescriptions, or confirm dispensing eligibility. |

**Right-side visual:** A premium medicine identity graph interface, not a drug catalog. The
visual should show a single medicine entity resolving across identity layers: brand name and
generic name · active ingredient · strength and dosage form · route and presentation ·
identifier mapping · jurisdictional classification · availability-signal linkage · governance
status.

**Required visual disclaimer:** *Illustrative example. Data availability, identifier coverage,
regulatory context, and jurisdictional mappings depend on licensed sources, approved use,
data quality, and contract scope.*

## 6. Section 2 — Medicine Identity Model

**Purpose:** Show the architecture clearly enough for data architects and CTOs while
remaining understandable to procurement and commercial buyers.

**H2:** Normalize medicine identity before availability becomes intelligence.

MediBase™ should be presented as a governed identity graph and classification layer. It must
show hierarchy, not a flat data table.

| Layer | What it does | Enterprise value |
|-------|--------------|------------------|
| Canonical Medicine Entity | Creates a normalized medicine entity across brand, generic, active ingredient, synonyms, spelling variants, and market-specific naming patterns. | Improves search precision, matching consistency, and data reuse across products. |
| Product and Presentation Layer | Models strength, dosage form, route, pack or presentation context where approved and operationally relevant. | Reduces ambiguity where similar names have different clinical or operational meaning. |
| Identifier Mapping Layer | Maps approved identifiers and references such as NDC, RxNorm/RxCUI, GTIN/GS1, DIN, dm+d, ATC, EAN/UPC, local codes, and partner identifiers where licensed and applicable. | Helps integrations connect local systems, pharmacy feeds, and enterprise datasets. |
| Jurisdictional Context Layer | Captures market, regulatory, prescription-status, controlled-category, and availability-context fields where supported and legally approved. | Supports jurisdiction-aware data products and governance. |
| Availability Linkage Layer | Connects normalized medicine identity to ZoikoAvail™ confidence signals, freshness metadata, pharmacy participation, and confirmation workflows. | Improves availability search and API output consistency. |
| Intelligence Alignment Layer | Aligns medicine entities across aggregated ZoikoSignal™ intelligence outputs such as access pressure, shortage movement, and demand patterns. | Makes enterprise intelligence more comparable across regions and products. |

**Critical distinction:** MediBase™ may support medicine matching. It must not be positioned
as a clinical substitution engine, dosing tool, prescription validator, interaction checker,
or treatment recommendation system.

## 7. Section 3 — Enterprise Use Cases

**Purpose:** Convert institutional visitors by showing why a medicine identity layer is
commercially valuable.

**H2:** Built for medicine data problems that break enterprise workflows.

| Use case | Problem solved | Primary CTA |
|----------|----------------|-------------|
| Search Normalization | Users search brands, generics, misspellings, strengths, and local names. MediBase™ helps normalize these inputs into safer search candidates and approved medicine entities. | Request Data Briefing |
| API Medicine Matching | Digital health and payer workflows need reliable medicine matching before availability signals can be embedded. | Discuss API Access |
| Cross-Market Data Alignment | Manufacturers, public-health teams, and global platforms need market-aware mappings across identifiers and jurisdictions. | Request Standards Review |
| Availability Signal Accuracy | ZoikoAvail™ depends on clean medicine identity to avoid misleading signals caused by ambiguous medicine names or presentations. | Explore ZoikoAvail™ API |
| Shortage and Demand Intelligence | ZoikoSignal™ requires consistent medicine identity to aggregate access pressure, shortage movement, and demand patterns responsibly. | Explore ZoikoSignal™ |
| Data Governance and Auditability | Enterprise teams need versioned, governed data definitions rather than ad hoc medicine lists. | View Data Governance |

**Sales logic:** The page must sell outcomes: cleaner matching, safer search, better API
integration, comparable intelligence, and governed data reuse. Do not oversell as clinical
certainty.

## 8. Section 4 — Standards, Quality, and Governance

**Purpose:** Build confidence with technical buyers while preventing unsupported standards
claims. Every reference to an identifier, terminology, or standard must be framed as
supported where licensed, available, approved, or contract-scoped.

**H2:** Standards-aware. Quality-controlled. Claim-governed.

| Governance band | Content direction |
|-----------------|-------------------|
| Identifier Coverage | NDC, RxNorm/RxCUI, GTIN/GS1, DIN, dm+d, ATC, EAN/UPC, local pharmacy or partner codes, and jurisdictional identifiers where licensed, available, and approved. |
| Interoperability Awareness | FHIR Medication/MedicationKnowledge alignment, ISO IDMP awareness, GS1 Healthcare alignment, structured API outputs, and data dictionary review where applicable. |
| Data Quality Tiers | Verified/reference-sourced, partner-supplied, mapped, inferred, deprecated, suppressed, and review-required states. |
| Provenance and Licensing Controls | Source attribution, license scope, version history, update cadence, jurisdiction restrictions, and downstream-use rules. |
| Safety and Suppression Rules | Controlled, restricted, high-risk, discontinued, recalled, ambiguous, or jurisdiction-sensitive medicines may require suppression, limited visibility, or additional review. |
| Versioning and Auditability | Schema versions, mapping versions, field-definition history, change logs, and review-state tracking. |

**Quality states to show in the visual system:**

| State | Meaning | User-facing action |
|-------|---------|--------------------|
| Verified mapping | Mapping is supported by approved reference data or reviewed source logic. | Use in approved workflows. |
| Partner-supplied mapping | Mapping was supplied by an approved partner or integration source. | Review source and contract scope. |
| Needs review | Mapping is ambiguous, incomplete, stale, or jurisdiction-sensitive. | Route to data governance review. |
| Deprecated | Medicine entity, identifier, or mapping is no longer current in the relevant context. | Prevent stale use and show replacement context where approved. |
| Suppressed | Entity or mapping is restricted from public or certain enterprise outputs due to governance, safety, or jurisdictional rules. | Do not expose unless separately approved. |

**Claim-control requirement:** Do not claim certification, completeness, regulatory
equivalence, global coverage, or official authority unless status, evidence, license rights,
and jurisdiction scope are verified and approved.

## 9. Section 5 — Access, Licensing, and Implementation

**Purpose:** Explain how enterprise teams can buy, test, and integrate MediBase™ without
forcing every buyer into a generic sales form.

**H2:** Evaluate, license, and integrate through governed access.

| Access path | Best for | Delivery format | CTA |
|-------------|----------|-----------------|-----|
| Data Briefing | Commercial, procurement, strategy, and executive teams evaluating MediBase™. | Guided briefing, data-scope review, commercial qualification. | Request MediBase™ Data Briefing |
| Data Dictionary Review | Data architects, informatics teams, and compliance reviewers. | Field definitions, entity model, quality states, source and scope notes. | Request Data Dictionary |
| Reference API Evaluation | Product and engineering teams integrating medicine identity lookup or matching. | REST API, sandbox, test keys where approved, example payloads. | Discuss API Access |
| Bulk or Licensed Data Product | Enterprise data platforms, analytics teams, public-sector programs, and partner systems. | Contract-scoped files, update cadence, schema documentation, licensing terms. | Request Data Licensing Review |
| Mapping and Implementation Workshop | Organizations with legacy medicine lists, local identifiers, or jurisdiction-specific datasets. | Mapping review, normalization plan, integration backlog. | Request Implementation Workshop |

**Commercial model signals:**

- Annual data licensing by jurisdiction, scope, and usage rights.
- API access tiers based on use case, rate limits, endpoints, and contract scope.
- Implementation and mapping services for enterprise data onboarding.
- Data dictionary and standards review available during procurement.
- All enterprise data use governed by Master Services Agreement, data-use restrictions, source licensing, and jurisdiction-specific terms.

**Lead form:**

| Field | Requirement |
|-------|-------------|
| Work email | Required |
| Full name | Required |
| Organization name | Required |
| Organization type | Required dropdown |
| Primary interest | Optional routing dropdown |
| Brief note | Optional free-text; do not request sensitive data |

Primary interest options: Data licensing, API access, medicine matching, data dictionary
review, health-system integration, public-health intelligence, manufacturer intelligence,
payer/digital health use case, security/procurement review, other.

## 10. Section 6 — Trust, Boundaries, and Close

**Purpose:** De-risk clinical, legal, procurement, privacy, and data licensing concerns in
one concise trust section.

**H2:** Governed medicine data, not medical advice.

| Trust row | Required copy direction |
|-----------|-------------------------|
| No Clinical Advice | MediBase™ does not recommend medicines, doses, treatments, substitutes, or clinical decisions. |
| No Prescription Validation | MediBase™ does not validate prescriptions, confirm patient eligibility, or approve dispensing. |
| No Patient Data Product | MediBase™ is a medicine identity data layer. It must not be marketed as a patient-level dataset. |
| No Exact Stock Exposure | MediBase™ does not expose exact pharmacy stock. Availability outputs are handled through governed ZoikoAvail™ workflows. |
| Jurisdiction-Aware Controls | Medicine identity, identifiers, classifications, and visibility may vary by jurisdiction, license scope, and regulatory context. |
| Licensed and Contract-Scoped Use | Enterprise access depends on contract, source licensing, data-use scope, and approved implementation pathway. |

**Close strip:**

| Element | Copy |
|---------|------|
| H3 | Build enterprise availability workflows on cleaner medicine identity. |
| Subheadline | Use MediBase™ to normalize medicine names, identifiers, presentations, and jurisdictional context for search, APIs, availability signals, and intelligence workflows. |
| Primary CTA | Request MediBase™ Data Briefing |
| Secondary CTA | Discuss Data/API Access |

## 11. Contextual States

| State | Behavior |
|-------|----------|
| Public visitor | Show public MediBase™ Data page with Request MediBase™ Data Briefing as the dominant CTA. |
| API-intent visitor | Route to ZoikoAvail™ API or data/API discussion while preserving MediBase™ source context. |
| Data architect visitor | Prioritize Request Data Dictionary, schema review, and implementation workshop CTAs. |
| Health-system visitor | Route to health-system data/workflow review and preserve MediBase™ interest. |
| Government or public-health visitor | Route to public-sector data and intelligence review with jurisdiction-aware language. |
| Patient or caregiver visitor | Route to Search Medicines or Availability Confidence. Do not push them into data licensing forms. |

## 12. Product and Workflow Requirements

**Entry points:** Footer: MediBase™ data · Enterprise Solutions page · ZoikoAvail™ API page ·
ZoikoSignal™ intelligence page · Health Systems page · Government & Public Health page ·
Developer/API documentation · Trust Center · Enterprise outreach campaigns.

**Minimum MediBase™ inquiry object:** Work email · Full name · Organization name ·
Organization type · Primary interest · Request source · Created date · Assigned queue ·
Status · Data-scope notes where provided.

**Potential product surfaces:** Medicine identity lookup · Medicine matching API · Identifier
mapping service · Jurisdictional classification context · Data dictionary portal · Change-log
viewer · Bulk export/download center · Mapping review queue · Suppression and review-state
dashboard · Integration sandbox.

**Do not collect by default:** Patient identifiers · PHI · Prescription images · Diagnosis ·
Symptoms · Clinical notes · Exact pharmacy stock · Confidential pharmacy inventory · API
secrets · Unlicensed third-party datasets · Commercially sensitive partner data through
public forms.

## 13. Security, Privacy, and Data Governance Requirements

| Area | Requirement |
|------|-------------|
| Public page guardrails | Do not expose patient-level data, exact stock, internal mapping formulas, proprietary source logic, restricted medicine handling rules, license-restricted datasets, or enterprise contract terms. |
| Enterprise data access | Role-based access, organization-level permissions, SSO readiness, MFA, secure session handling, audit logging, contract-scoped entitlements, and no public indexing of authenticated data surfaces. |
| Data governance | Versioned schemas, mapping history, source and license metadata, review states, controlled-medicine suppression rules, update cadence, and approved downstream-use rules. |
| Privacy | MediBase™ should not require patient data. Any linkage to user behavior or availability signals must remain governed through ZoikoMeds privacy architecture. |
| Analytics guardrail | Do not send patient identifiers, raw medicine names tied to users, PHI, exact stock, internal scores, licensed source data, API credentials, or enterprise confidential data into general marketing analytics. |

## 14. Accessibility Requirements

- WCAG 2.2 AA minimum.
- Identity graph visual must have a text equivalent.
- Tables must be keyboard navigable and readable on mobile.
- Status labels must use icon, text, and color; never color alone.
- Forms must use visible labels and accessible error states.
- Touch targets must be at least 44px, with 48px preferred.
- Complex identifier examples must use plain-language explanations.
- Reduced-motion support required.
- Dashboard or graph visuals must include accessible summaries.

## 15. SEO, AEO, and Schema Requirements

**Recommended schema:** WebPage · Organization · BreadcrumbList · FAQPage only if formal FAQ
content is included and approved · SoftwareApplication only if legal and product review
approve the description.

**Avoid unless legally approved:** MedicalWebPage · Drug · Pharmacy · MedicalBusiness · Offer
if it implies medicine sales or data-product pricing not publicly approved.

**Recommended answer blocks:**

| Question | Answer-ready copy |
|----------|-------------------|
| What is MediBase™? | MediBase™ is ZoikoMeds' governed medicine identity and normalization data layer for enterprise search, API, availability, and intelligence workflows. |
| Does MediBase™ provide clinical advice? | No. MediBase™ supports medicine identity matching and data normalization. It does not recommend medicines, doses, substitutions, or treatment decisions. |
| Can enterprises license MediBase™ data? | Qualified organizations may request MediBase™ data briefings, data dictionary review, API access, or contract-scoped licensing discussions. |
| Does MediBase™ contain patient data? | MediBase™ is a medicine identity data layer. It should not be marketed as a patient-level data product. |
| How does MediBase™ connect to ZoikoAvail™ and ZoikoSignal™? | MediBase™ normalizes medicine identity so ZoikoAvail™ can produce more consistent availability signals and ZoikoSignal™ can align aggregated intelligence outputs. |

## 16. Analytics Funnel

| Stage | Events | Purpose |
|-------|--------|---------|
| 1. Arrival | medibase_page_viewed; medibase_hero_cta_visible | Measure enterprise data-product interest. |
| 2. Data engagement | identity_model_viewed; standards_band_viewed; data_quality_state_viewed; governance_section_viewed | Understand which data concepts drive evaluation. |
| 3. Intent | medibase_briefing_clicked; data_dictionary_clicked; api_access_clicked; standards_review_clicked | Separate commercial, data, API, and governance intent. |
| 4. Conversion | medibase_form_started; medibase_form_submitted; data_crm_routed; medibase_calendar_booked | Measure conversion into enterprise data pipeline. |

**Analytics privacy guardrail:** Do not send patient identifiers, raw medicine names tied to
users, PHI, exact locations, exact stock, internal mapping formulas, licensed source data,
API credentials, or enterprise confidential information into general analytics.

## 17. Legal and Trust Copy

Recommended page-level trust copy: MediBase™ supports enterprise medicine identity,
normalization, identifier mapping, and jurisdictional context for governed ZoikoMeds
availability and intelligence workflows. MediBase™ does not provide medical advice, prescribe,
dispense, sell, deliver, reserve, recommend, allocate, guarantee medicines, validate
prescriptions, recommend substitutions, confirm eligibility, expose exact public pharmacy
stock, or operate as a patient-level data product. Enterprise access and outputs are subject
to contract, source licensing, privacy controls, jurisdiction-specific laws, data-use
restrictions, and approved governance rules.

## 18. Acceptance Criteria

1. It clearly positions MediBase™ as the enterprise medicine identity and normalization layer behind ZoikoMeds.
2. It uses one dominant CTA: Request MediBase™ Data Briefing.
3. It explains the relationship between MediBase™, ZoikoAvail™, and ZoikoSignal™.
4. It presents medicine identity as a governed graph and classification layer, not a flat drug list.
5. It includes identifier, standards, provenance, versioning, quality, and jurisdictional governance language.
6. It avoids clinical advice, substitution, prescribing, dispensing, stock guarantees, prescription validation, and eligibility claims.
7. It clearly states that MediBase™ is not a patient-level data product.
8. It protects licensed source data, exact stock, patient data, pharmacy-sensitive data, internal mapping logic, and enterprise confidential data.
9. It supports SEO/AEO for medicine identity data, medicine data API, pharmaceutical reference data, and drug data normalization.
10. It meets WCAG 2.2 AA accessibility standards.
11. It is ready for front-end design, enterprise sales, API/product, data governance, legal review, compliance review, privacy review, security review, analytics, and engineering handoff.

**Final recommendation:** The MediBase™ data page should be built as the enterprise
data-substrate page under Enterprise & Intelligence. Its promise is simple: Normalize medicine
identity. Govern data use. Power availability intelligence. The correct next Enterprise &
Intelligence footer wireframe after approval is Health systems.

---

# PART 2: ZoikoAvail™ API Page — Tier-0 Wireframe Specification

**ZOIKOMEDS · ZoikoAvail™ API Page · Detailed Wireframe Specification**
Enterprise & Intelligence Footer Heading | Final Export
Prepared for ZoikoMeds — Global Medicine Availability Infrastructure

**Footer Category:** Enterprise & Intelligence · **Footer Link:** ZoikoAvail™ API
**Recommended URL:** `/enterprise/zoikoavail-api` or `/api/zoikoavail`
**Language:** American English
**Standard:** Fortune 10 quality, Tier-1 product, SEO/AEO optimized, conversion-led, compliance-aware

**Critical refinement applied:** The page is structured as an enterprise API evaluation
surface, not a developer documentation page, not a consumer search page, and not a pharmacy
inventory feed. The public page sells the business value and governance of API access;
technical docs and sandbox access remain gated behind verified review.

## 1. Page Doctrine

The ZoikoAvail™ API page is the enterprise integration page for confidence-based medicine
availability infrastructure. It is not a public API catalog, not a developer sandbox without
qualification, not a pharmacy inventory feed, not an exact-stock endpoint, not a dispensing or
reservation API, and not a clinical decision-support system.

**Core buyer question:** How can my organization integrate governed medicine availability
signals into our product, care workflow, member experience, or institutional platform without
exposing exact stock, patient data, or pharmacy-sensitive information?

The answer must be clear: ZoikoAvail™ API gives approved enterprise customers contract-scoped
access to availability confidence, freshness metadata, pharmacy signal context, and
confirmation-aware workflows — governed by permissions, jurisdiction, privacy controls, and
exact-stock suppression.

This page must convert technical buyers into API evaluations while reassuring compliance,
security, pharmacy, and procurement reviewers that ZoikoMeds is a governed infrastructure
provider rather than a public stock database.

## 2. Strategic Role

| Item | Specification |
|------|---------------|
| Primary audience | CTOs, CIOs, product leaders, digital health platforms, telehealth companies, payer and PBM product teams, health-system integration teams, pharmacy platform teams, enterprise architects, data teams, security reviewers, and procurement teams. |
| Primary goal | Convert qualified enterprise visitors into API evaluation, sandbox review, security pack, commercial briefing, or integration discussion. |
| Secondary goal | Route buyers who need intelligence or medicine identity data to ZoikoSignal™ or MediBase™ without diluting the API page. |
| Primary CTA | Request API Access |
| Secondary CTA | View API Capabilities |
| Contextual CTAs | Request Technical Briefing; Download API Overview; Request Security Pack; Discuss Integration; Explore MediBase™; View Governance. |

## 3. SEO and AEO Targeting

| Item | Value |
|------|-------|
| Meta title | Medicine Availability API \| ZoikoAvail™ API \| ZoikoMeds |
| Meta description | ZoikoAvail™ API gives approved enterprises governed access to confidence-based medicine availability signals, freshness metadata, pharmacy confirmation pathways, and integration-ready workflows. |
| Indexing | Index the public API product page. Noindex gated docs, sandbox, credentials, API console, support tickets, logs, and authenticated developer surfaces. |

**Primary SEO keywords:** medicine availability API · pharmacy availability API · medication
availability API · drug availability API · pharmacy stock API · medicine stock API ·
healthcare availability API · medication access API · pharmacy confirmation API · medicine
shortage API · digital health pharmacy availability integration · telehealth medication
availability API

**AEO questions this page must answer:**

- What is ZoikoAvail™ API?
- Can my platform integrate medicine availability checks?
- Does ZoikoAvail™ API show exact pharmacy stock?
- Can ZoikoAvail™ API support telehealth workflows?
- Can payers or PBMs use medicine availability signals?
- What data does the API return?
- Can the API support pharmacy confirmation workflows?
- How does the API protect patient and pharmacy data?
- Does the API provide clinical advice?
- How do enterprises request API access?

## 4. Page Architecture — Six Sections

| Section | Job |
|---------|-----|
| 1. Hero | Position ZoikoAvail™ API as governed medicine availability infrastructure and expose API access CTA. |
| 2. API Capability Model | Show the core API capabilities without exposing full endpoint documentation publicly. |
| 3. Integration Use Cases | Route buyers by product need: telehealth, payer, provider, pharmacy, digital health, and platform workflows. |
| 4. API Governance and Data Controls | De-risk exact stock, PHI, patient inference, pharmacy confidentiality, and controlled medicine concerns. |
| 5. Developer Access, Sandbox, and Procurement | Explain the gated evaluation path, documentation access, security review, and commercial structure. |
| 6. Access Pathways and Close | Convert into API access, technical briefing, security review, or data/product routing. |

## 5. Section 1 — Hero

**Purpose:** The hero must make clear that ZoikoAvail™ API is an enterprise-grade availability
confidence layer, not a public stock feed. It should attract technical buyers while
immediately setting governance expectations.

| Element | Copy |
|---------|------|
| Eyebrow | ZOIKOAVAIL™ API |
| H1 | Integrate medicine availability signals into regulated healthcare workflows. |
| Subheadline | ZoikoAvail™ API gives approved organizations access to confidence-based medicine availability signals, freshness metadata, pharmacy confirmation pathways, and location-aware availability workflows — without exposing exact public stock or replacing clinical judgment. |
| Primary CTA | Request API Access |
| Secondary CTA | View API Capabilities |
| Contextual link | Request Security Pack |
| Hero microcopy | API access is contract-scoped, jurisdiction-aware, and governed by privacy, security, pharmacy, and data-use controls. |

**Right-side visual:** Use an abstract API console/dashboard preview, not code-heavy
documentation. The visual should show a request-to-response flow, API health status,
confidence signal object, freshness metadata, governance badge, and exact-stock suppression
indicator. Example modules: API status, endpoint family selector, confidence signal response,
freshness label, confirmation pathway flag, jurisdiction control, sandbox status, audit log
badge.

**Required visual disclaimer:** *Illustrative example. API access, fields, endpoints, rate
limits, and data outputs are governed by contract, permissions, jurisdiction, and approved
data scope.*

## 6. Section 2 — API Capability Model

**Purpose:** This section must give product, engineering, and enterprise buyers a clear sense
of what the API enables without publishing exploitable endpoint details or implying public
exact-stock access.

**H2:** A governed API layer for availability-aware products.

**Capability modules:**

- **Availability Confidence Signals** — Return confidence-based availability indicators for
  medicine, geography, radius, and approved pharmacy-participation context. *Enterprise value:*
  Embed safer availability checks without public stock counts. *CTA:* Request API Access.
- **Freshness and Signal Metadata** — Expose freshness context and signal-quality information
  where approved, so platforms can show when direct confirmation is needed. *Enterprise value:*
  Reduce false certainty and improve user guidance. *CTA:* View API Capabilities.
- **Medicine Match Support** — Use MediBase™-powered matching context for brand, generic,
  strength, form, and jurisdiction-aware medicine identity logic. *Enterprise value:* Improve
  search precision and reduce medicine-name ambiguity. *CTA:* Explore MediBase™.
- **Pharmacy Confirmation Pathways** — Support confirmation-aware flows where participating
  verified pharmacies allow structured confirmation options. *Enterprise value:* Guide users
  toward the right next step without creating reservations. *CTA:* Discuss Confirmation Workflows.
- **Location-Aware Availability Workflows** — Support radius, service-area, pharmacy-location,
  and jurisdiction-aware search workflows where approved. *Enterprise value:* Embed availability
  checks into patient, member, or care-team journeys. *CTA:* Request Technical Briefing.
- **Event and Update Patterns** — Support scheduled pulls, webhook/event patterns, or
  streaming-like workflows where product readiness and contracts allow. *Enterprise value:* Keep
  products aligned with changing signal states while respecting rate limits and data controls.
  *CTA:* Discuss Integration.

**Required boundary:** ZoikoAvail™ API does not return public exact stock quantities,
dispensing eligibility, clinical recommendations, prescription validation, or guaranteed
availability.

## 7. Section 3 — Integration Use Cases

**Purpose:** Convert API interest by mapping ZoikoAvail™ to buyer-specific product outcomes.
The page should sell integration value, not just list endpoints.

**H2:** Built for platforms where medicine access affects the user journey.

- **Telehealth and Virtual Care** — Add availability-aware next steps after a clinical
  encounter while keeping clinical decisions outside ZoikoAvail™. *Best fit:* Telehealth
  platforms, virtual clinics, asynchronous care providers. *CTA:* Discuss Telehealth Integration.
- **Payer and Member Support** — Help members understand availability friction and pharmacy
  confirmation steps in covered-care or access-support workflows. *Best fit:* Payers, PBMs,
  member-support platforms. *CTA:* Request Payer Briefing.
- **Provider and Care Navigation** — Support discharge, care coordination, and patient access
  workflows with confidence-based availability guidance. *Best fit:* Health systems, care teams,
  patient navigation platforms. *CTA:* Request Provider Workflow Briefing.
- **Digital Health and Patient Apps** — Embed saved search, alert, and availability signal
  experiences into approved digital health journeys. *Best fit:* Digital health companies,
  patient support apps, chronic-care platforms. *CTA:* Request API Access.
- **Enterprise Pharmacy Platforms** — Support pharmacy-group, verified network, confirmation,
  or signal workflows where contract and permissions allow. *Best fit:* Enterprise pharmacy
  operators, pharmacy systems, integration partners. *CTA:* Discuss Pharmacy Integration.
- **Public-Sector and Access Programs** — Support approved population access workflows with
  governed availability signal outputs and jurisdiction-aware controls. *Best fit:* Government,
  public health, emergency preparedness, NGO programs. *CTA:* Request Public Health API Briefing.

## 8. Section 4 — API Governance and Data Controls

**Purpose:** This is the trust core. It must satisfy security, compliance, pharmacy, and
procurement reviewers before they agree to an API evaluation.

**H2:** Availability signals governed before they reach your product.

| Governance area | Required standard |
|-----------------|-------------------|
| Exact-stock suppression | Public API outputs must not expose exact pharmacy stock quantities unless a separately governed, non-public, contract-specific workflow is approved. |
| No clinical advice | API outputs must not recommend medicines, substitutes, doses, treatments, clinical actions, or prescribing decisions. |
| No dispensing approval | API outputs must not confirm prescription validity, patient eligibility, pharmacist approval, or medicine fulfillment. |
| Privacy protection | API outputs must avoid identifiable patient-level intelligence, PHI leakage, and user-level health inference. |
| Pharmacy confidentiality | Outputs must protect pharmacy inventory, workflow, pricing, operational notes, and participation-sensitive data. |
| Jurisdiction-aware controls | Data access, medicine categories, controlled medicine logic, and output fields must respect local rules and contract scope. |
| Controlled medicine safeguards | Controlled, restricted, high-risk, or jurisdiction-sensitive medicines may be suppressed, limited, masked, or routed through additional controls. |
| Audit and observability | API access, credentials, permissions, key events, and sensitive calls must be logged for governance and support. |

**Public claim-control rule:** Do not publish endpoint fields, data categories, availability
levels, response examples, or coverage claims unless product, legal, privacy, security, and
pharmacy operations have approved them.

## 9. Section 5 — Developer Access, Sandbox, and Procurement

**Purpose:** The API page must convert technical buyers without opening an uncontrolled
developer surface. Public content sells the API; gated content provides docs, sandbox, keys,
and implementation details.

**H2:** Enterprise API evaluation without uncontrolled data exposure.

| Evaluation stage | What happens | Primary CTA |
|------------------|--------------|-------------|
| 1. API Interest | Buyer submits API access request with organization type, use case, and integration context. | Request API Access |
| 2. Qualification | ZoikoMeds reviews organization, jurisdiction, use case, data need, and risk profile. | Request Technical Briefing |
| 3. Security and Governance Review | Security, privacy, data-use, procurement, and legal review materials are shared where appropriate. | Request Security Pack |
| 4. Sandbox Access | Approved teams receive contract-scoped sandbox documentation, test credentials, sample responses, and rate-limit guidance. | Request Sandbox Review |
| 5. Implementation Planning | Technical and commercial teams define endpoints, integration method, success criteria, support model, and launch path. | Discuss Integration |
| 6. Production Approval | Production access requires signed terms, credential governance, monitoring, support routing, and approved data scope. | Request Commercial Briefing |

**Commercial model signals:**

- API licensing — usage-tiered and contract-scoped.
- Sandbox evaluation — gated and qualification-based.
- Implementation support — scoped by integration complexity.
- Jurisdiction expansion — reviewed by market, compliance, and data readiness.
- Enterprise support — governed by service model and contract tier.
- Master Services Agreement and data-use restrictions required for production use.

## 10. Section 6 — Access Pathways and Close

**Purpose:** Route technical, commercial, security, and product buyers to the right conversion
path.

**H2:** Start with the right API route.

| Pathway | For | CTA |
|---------|-----|-----|
| API Evaluation | CTOs, product teams, engineering teams, digital health platforms, and integration buyers. | Request API Access |
| Technical Briefing | Enterprise architects, data teams, engineering leads, and platform teams evaluating implementation. | Request Technical Briefing |
| Security and Procurement Review | InfoSec, privacy, legal, procurement, and compliance reviewers. | Request Security Pack |
| Medicine Data Review | Teams needing medicine identity normalization before availability integration. | Explore MediBase™ |

**API Access Form:**

| Field group | Requirement |
|-------------|-------------|
| Required fields | Work email; full name; organization name; organization type. |
| Optional field | Brief note about your API use case, integration workflow, or availability data need. |
| Organization type options | Telehealth / digital health; health system; payer / PBM; provider platform; enterprise pharmacy group; government / public health; data / platform partner; other. |
| Primary interest options | Availability confidence API; pharmacy confirmation workflow; medicine matching; saved search / alert integration; public-health workflow; security review; commercial partnership. |
| Success state | Thank you. Your API access request has been received. ZoikoMeds will route your request to the appropriate API, technical, security, commercial, or governance team. |

**Close strip:**

- **H3:** Build availability-aware products on governed infrastructure.
- **Subheadline:** Use ZoikoAvail™ API to integrate confidence-based medicine availability
  signals, freshness metadata, confirmation-aware workflows, and jurisdiction-aware controls
  into regulated healthcare products.
- **Primary CTA:** Request API Access
- **Secondary CTA:** Request Technical Briefing

## 11. Contextual States

| State | Required behavior |
|-------|-------------------|
| Public visitor | Show the public ZoikoAvail™ API page with Request API Access as the dominant CTA. |
| Developer-intent visitor | Route to gated documentation access flow after qualification. Do not expose live docs or keys publicly. |
| Security/procurement visitor | Route to security pack and procurement review path. |
| MediBase-intent visitor | Route to MediBase™ data page where medicine identity is the primary need. |
| ZoikoSignal-intent visitor | Route to ZoikoSignal™ intelligence page where dashboards, reports, or institutional intelligence are the primary need. |
| Patient/caregiver visitor | Route to Search Medicines. Do not push consumers into API forms. |

## 12. Product and API Requirements

**Entry points:** Footer: ZoikoAvail™ API · Enterprise Solutions page · ZoikoSignal™
Intelligence page · MediBase™ Data page · Developer portal · API documentation teaser · Trust
Center · Enterprise outreach campaigns.

**Minimum API inquiry object:** Work email · Full name · Organization name · Organization type ·
Primary interest · Use-case summary · Request source · Created date · Assigned queue · Status.

**Do not collect in public forms:** Patient identifiers · PHI · Prescription records · Raw
medicine search data tied to individuals · Exact pharmacy stock · Pharmacy inventory files ·
API secrets · Access tokens · Confidential procurement documents · Controlled medicine
operational details.

## 13. Security, Privacy, and Data Governance Requirements

| Area | Requirement |
|------|-------------|
| Authentication | Gated developer surfaces require secure authentication, MFA where appropriate, and organization-level access control. |
| Credential management | API keys, client credentials, secrets, signing keys, and tokens must be rotated, scoped, encrypted, monitored, and revocable. |
| Rate limits | Rate limits must be contract-scoped and abuse-aware. High-risk patterns should trigger review. |
| Audit logs | Credential creation, endpoint access, scope changes, production approvals, and sensitive requests must be auditable. |
| Data minimization | Return only fields required for the approved use case and contract scope. |
| No public exact stock | Exact public stock counts are suppressed. Any exceptional non-public workflow requires explicit governance approval. |
| Privacy | No identifiable patient-level intelligence outputs. PHI handling requires a separate governed workflow. |
| Controlled medicines | Jurisdiction-aware suppression, masking, rate limiting, or exclusion may apply. |

## 14. Accessibility and Developer Experience Requirements

- The public page must meet WCAG 2.2 AA.
- API diagrams must have text equivalents.
- Code snippets, if shown publicly, must be readable, copyable, and screen-reader accessible.
- Forms must use visible labels, clear errors, and assistive-technology-friendly success states.
- CTA labels must be descriptive: Request API Access, Request Technical Briefing, Request Security Pack.
- Do not rely on color alone for API status, signal state, or governance badges.
- Touch targets must be at least 44px, with 48px preferred.
- Dashboard mockups must include accessible summaries.

## 15. SEO, AEO, and Schema Requirements

Use legally accurate structured data only.

| Recommended | Avoid unless approved |
|-------------|-----------------------|
| WebPage; Organization; BreadcrumbList; FAQPage if approved; SoftwareApplication only if product/legal approve the description. | MedicalWebPage; Pharmacy; Drug; Offer; Product if it implies medicine commerce; APIReference unless documentation is public and approved. |

**Recommended answer blocks:**

- **What is ZoikoAvail™ API?** ZoikoAvail™ API is ZoikoMeds' governed API layer for
  confidence-based medicine availability signals, freshness metadata, and confirmation-aware
  workflows.
- **Does ZoikoAvail™ API show exact pharmacy stock?** No. ZoikoAvail™ API is designed around
  confidence-based signals and exact-stock suppression unless a separate non-public,
  contract-governed workflow is approved.
- **Can digital health platforms integrate ZoikoAvail™ API?** Yes. Approved digital health,
  telehealth, payer, provider, and enterprise platforms may request API access for governed
  availability workflows.
- **Does ZoikoAvail™ API provide medical advice?** No. The API does not provide medical,
  clinical, prescribing, substitution, or dispensing advice.

## 16. Analytics Funnel

| Stage | Events | Purpose |
|-------|--------|---------|
| 1. Arrival | zoikoavail_api_page_viewed; api_capability_visible | Measure API-intent traffic. |
| 2. Engagement | api_capability_clicked; use_case_viewed; governance_section_viewed; security_pack_clicked | Understand which API capability and trust concern drives interest. |
| 3. Intent | request_api_access_clicked; technical_briefing_clicked; security_pack_clicked; sandbox_review_clicked | Separate API, technical, security, and sandbox intent. |
| 4. Conversion | api_form_started; api_form_submitted; api_crm_routed; api_briefing_booked | Measure conversion into the enterprise API pipeline. |

**Analytics privacy guardrail:** Do not send patient identifiers, raw medicine names tied to
users, PHI, exact locations, exact stock, pharmacy inventory data, internal confidence scores,
API credentials, or enterprise confidential information into general analytics.

## 17. Legal and Trust Copy

Recommended page-level trust copy: ZoikoAvail™ API provides approved enterprises with governed,
contract-scoped access to confidence-based medicine availability signals, freshness metadata,
and confirmation-aware workflows. ZoikoAvail™ API does not provide medical advice, prescribe,
dispense, sell, deliver, reserve, recommend, allocate, or guarantee medicines; validate
prescriptions; recommend substitutions; confirm eligibility; expose exact public pharmacy stock;
or output identifiable patient-level intelligence. API access and outputs are subject to
contract, permissions, privacy controls, jurisdiction-specific laws, data-use restrictions, rate
limits, and approved governance rules.

## 18. Acceptance Criteria

1. It positions ZoikoAvail™ API as governed medicine availability infrastructure, not a public stock feed.
2. It uses one dominant CTA: Request API Access.
3. It explains API capabilities without publishing exploitable endpoint details.
4. It routes buyers by product need (telehealth, payer, provider, digital health, pharmacy, public sector).
5. It de-risks exact stock, PHI, patient inference, pharmacy confidentiality, and controlled-medicine concerns.
6. It describes a gated evaluation path (interest → qualification → security review → sandbox → implementation → production).
7. It avoids clinical advice, dispensing approval, prescription validation, eligibility, and availability guarantees.
8. It keeps live docs, sandbox, and credentials behind qualification and noindex.
9. It supports SEO/AEO for medicine availability API, pharmacy availability API, and healthcare availability API.
10. It meets WCAG 2.2 AA accessibility standards.
11. It is ready for front-end design, enterprise sales, API/product, security review, procurement, legal, privacy, analytics, and engineering handoff.

**Final recommendation:** The ZoikoAvail™ API page should be built as the enterprise integration
page under Enterprise & Intelligence. Its promise is simple: Integrate availability confidence.
Suppress exact stock. Stay governed. The correct next Enterprise & Intelligence footer wireframe
after approval is ZoikoSignal™ intelligence.

---

# PART 3: ZoikoSignal™ Intelligence Page — Tier-0 Wireframe Specification

**ZOIKOMEDS · ZoikoSignal™ Intelligence Page · Detailed Wireframe Specification | Final**
Prepared for ZoikoMeds — Global Medicine Availability Infrastructure

**Footer Category:** Enterprise & Intelligence · **Footer Link:** ZoikoSignal™ intelligence
**Recommended URL:** `/enterprise/zoikosignal` or `/zoikosignal`
**Standard:** Fortune 10 quality, Tier-1 product, SEO/AEO optimized, conversion-led, compliance-aware

**Critical refinement applied:** The page is an enterprise intelligence-product page for
aggregated, anonymized shortage and access intelligence. It is not a public shortage tracker,
not a patient-level dataset, not a pharmacy-inventory leaderboard, and not a real-time
exact-stock feed. All intelligence outputs are aggregated, bucketed, and governed by
k-anonymity thresholds before display or export.

## 1. Page Doctrine

The ZoikoSignal™ intelligence page is the enterprise intelligence page for aggregated,
anonymized medicine shortage and access intelligence. It explains how ZoikoMeds converts
searches, zero-result events, stock confirmations, restock patterns, and geographic demand into
governed intelligence for pharmacies, manufacturers, distributors, health systems, governments,
and public-health stakeholders.

It is not a public shortage-tracking dashboard, not a patient-level behavior product, not a
pharmacy-shaming tool, not an exact-stock feed, and not a clinical or prescribing intelligence
system.

**Core question:** How can an institution understand medicine access pressure, shortage
movement, and unmet demand across regions and products without exposing individual patients,
individual pharmacies, or exact stock?

The answer must be precise: ZoikoSignal™ provides aggregated, anonymized, k-anonymity-governed
intelligence about demand movement, shortage pressure, unmet demand, and restock signals — never
identifiable patient behavior, never exact pharmacy stock, and never clinical recommendations.

## 2. Strategic Role

| Item | Specification |
|------|---------------|
| Footer category | Enterprise & Intelligence |
| Footer link | ZoikoSignal™ intelligence |
| Recommended URL | `/enterprise/zoikosignal` |
| Page type | Enterprise intelligence product page |
| Primary audience | Manufacturers, distributors, wholesalers, pharmacy groups, payers, health systems, government and public-health agencies, NGOs, market-access teams, supply-chain teams, and health-economics/analytics leaders. |
| Primary goal | Convert qualified organizations into ZoikoSignal™ intelligence briefings, report evaluations, dashboard access discussions, and data-licensing conversations. |
| Secondary goal | Route API-need and medicine-identity-need visitors to ZoikoAvail™ or MediBase™ without diluting the intelligence page. |
| Primary CTA | Request ZoikoSignal™ Intelligence Briefing |
| Secondary CTA | View Intelligence Capabilities |
| Contextual CTAs | Request Sample Report; Discuss Dashboard Access; Request Data Licensing Review; Explore MediBase™; Explore ZoikoAvail™ API; View Data Governance. |

## 3. SEO and AEO Targeting

| Item | Value |
|------|-------|
| Meta title | Medicine Shortage & Access Intelligence \| ZoikoSignal™ \| ZoikoMeds |
| Meta description | ZoikoSignal™ delivers aggregated, anonymized medicine shortage, demand, and access intelligence for manufacturers, health systems, payers, and public-health teams — governed by k-anonymity and jurisdictional controls. |
| Indexing | Index the public intelligence product page. Noindex authenticated dashboards, report libraries, export surfaces, and licensed data views. |

**Primary SEO keywords:** medicine shortage intelligence · drug shortage data · medication
access intelligence · pharmaceutical demand data · medicine demand signals · drug shortage
analytics · access-risk intelligence · unmet demand data · pharmaceutical market-access
intelligence · public-health shortage monitoring · anonymized medicine demand data.

**AEO questions this page must answer:**

- What is ZoikoSignal™?
- Does ZoikoSignal™ expose individual patient behavior?
- Does ZoikoSignal™ expose exact pharmacy stock?
- What intelligence outputs does ZoikoSignal™ provide?
- How is ZoikoSignal™ anonymized?
- What is k-anonymity and how does ZoikoSignal™ apply it?
- Can manufacturers or health systems license ZoikoSignal™ intelligence?
- How does ZoikoSignal™ connect to MediBase™ and ZoikoAvail™?
- Is ZoikoSignal™ a clinical or prescribing tool?
- How does ZoikoSignal™ handle jurisdictional data?

## 4. Page Architecture — Six Sections

| Section | Job |
|---------|-----|
| 1. Hero | Position ZoikoSignal™ as governed, anonymized access & shortage intelligence. |
| 2. Intelligence Model | Show what signals are aggregated and what outputs are produced. |
| 3. Stakeholder Use Cases | Convert by mapping intelligence to manufacturer, distributor, payer, health-system, and public-sector outcomes. |
| 4. Anonymization and Governance | De-risk patient re-identification, pharmacy exposure, and exact-stock concerns; explain k-anonymity. |
| 5. Access, Reports, and Licensing | Explain briefings, sample reports, dashboards, and data licensing paths. |
| 6. Trust, Boundaries, and Close | De-risk clinical, privacy, and procurement review and close with conversion. |

## 5. Section 1 — Hero

| Element | Copy |
|---------|------|
| Eyebrow | ZOIKOSIGNAL™ INTELLIGENCE |
| H1 | Understand medicine access pressure without exposing anyone. |
| Subheadline | ZoikoSignal™ converts aggregated, anonymized search, availability, and restock signals into governed intelligence about demand movement, shortage pressure, and unmet demand — across medicines, regions, and time. |
| Primary CTA | Request ZoikoSignal™ Intelligence Briefing |
| Secondary CTA | View Intelligence Capabilities |
| Contextual link | View Data Governance |
| Hero microcopy | ZoikoSignal™ outputs are aggregated and k-anonymity-governed. It does not expose individual patients, individual pharmacies, exact stock, or clinical recommendations. |

**Right-side visual:** An aggregated intelligence dashboard preview showing demand-movement
trend, shortage-pressure bars, unmet-demand list, and restock signals — with a visible
"k-anonymity ≥ N" governance badge. No pharmacy names, no patient rows, no exact counts.

**Required visual disclaimer:** *Illustrative example. Intelligence coverage, granularity,
regions, and outputs depend on data availability, k-anonymity thresholds, jurisdiction, and
contract scope.*

## 6. Section 2 — Intelligence Model

**H2:** From anonymized signals to governed intelligence.

| Signal input | What it captures | Governed output |
|--------------|------------------|-----------------|
| Search signals | Aggregate demand for governed medicine entities by region and time. | Demand movement and top-demand intelligence. |
| Zero-result events | Searches that returned no available medicine, aggregated. | Unmet-demand and access-gap intelligence. |
| Stock confirmations | Confirmed availability signals from participating verified pharmacies, aggregated. | Supply-signal and restock intelligence. |
| Inventory/restock changes | Directional restock movement, aggregated and de-identified. | Restock-pattern and recovery intelligence. |
| Geographic demand | Region/jurisdiction-level demand concentration. | Access-pressure and regional-risk intelligence. |

**Output families:** Demand movement · Shortage pressure (zero-result rate per medicine) · Unmet
demand (top zero-result terms, k-anonymity applied) · Restock/recovery signals · Regional access
risk. All outputs are aligned to **MediBase™** medicine identity for cross-region comparability.

**Required boundary:** ZoikoSignal™ does not output individual patient behavior, individual
pharmacy inventory, exact stock counts, prescriber data, or clinical/prescribing recommendations.

## 7. Section 3 — Stakeholder Use Cases

**H2:** Built for the organizations that respond to medicine access pressure.

- **Manufacturers & Market Access** — See where demand pressure and unmet demand are building to
  inform supply, allocation, and access programs. *CTA:* Request Intelligence Briefing.
- **Distributors & Wholesalers** — Understand regional demand movement and restock recovery
  patterns. *CTA:* Discuss Dashboard Access.
- **Pharmacy Groups** — Benchmark aggregate demand and shortage pressure across regions without
  exposing individual store data. *CTA:* Request Sample Report.
- **Payers & PBMs** — Anticipate access friction affecting members and covered therapies. *CTA:*
  Request Payer Briefing.
- **Health Systems** — Anticipate access gaps affecting discharge and care-navigation workflows.
  *CTA:* Explore Health Systems.
- **Government & Public Health** — Monitor jurisdiction-level access risk and preparedness with
  anonymized, aggregated intelligence. *CTA:* Explore Government & Public Health.

## 8. Section 4 — Anonymization and Governance

**H2:** Intelligence you can act on, governed so no one is exposed.

| Governance area | Required standard |
|-----------------|-------------------|
| K-anonymity thresholds | Aggregates below the configured k-anonymity threshold are suppressed from display and export; the applied threshold is surfaced to the user. |
| Aggregation and bucketing | Signals are aggregated over time buckets (e.g., daily/weekly) and geographic buckets before output; no per-event or per-user rows. |
| No patient-level output | ZoikoSignal™ must not output identifiable patient behavior, individual search histories, or PHI. |
| No individual pharmacy exposure | Outputs must not identify or rank individual pharmacies or expose their inventory. |
| No exact stock | Outputs express pressure, movement, and rates — never exact stock counts. |
| Jurisdiction-aware controls | Regions, medicine categories, and controlled-medicine handling respect local rules and contract scope. |
| Provenance and versioning | Aggregation logic, thresholds, and schema are versioned and auditable. |

**Claim-control requirement:** Do not present ZoikoSignal™ as a definitive shortage register,
regulatory shortage list, or clinical intelligence source unless status, evidence, and
jurisdiction scope are verified and approved.

## 9. Section 5 — Access, Reports, and Licensing

**H2:** Evaluate intelligence through governed access.

| Access path | Best for | Delivery format | CTA |
|-------------|----------|-----------------|-----|
| Intelligence Briefing | Commercial, strategy, market-access, and executive teams. | Guided briefing and scope review. | Request ZoikoSignal™ Intelligence Briefing |
| Sample Report | Analysts and evaluators assessing output quality. | Redacted, aggregated sample report. | Request Sample Report |
| Dashboard Access | Teams needing recurring aggregated views. | Contract-scoped authenticated dashboard, filters, exports. | Discuss Dashboard Access |
| Licensed Data Product | Enterprise analytics, public-sector programs, partners. | Contract-scoped aggregated data, update cadence, schema docs. | Request Data Licensing Review |

**Commercial model signals:** annual intelligence licensing by scope/region/usage · dashboard
access tiers · report subscriptions · public-sector programs reviewed by market and compliance ·
all use governed by MSA, data-use restrictions, and jurisdictional terms.

**Lead form:** Work email (req) · Full name (req) · Organization name (req) · Organization type
(req dropdown) · Primary interest (optional routing) · Brief note (optional; no sensitive data).

## 10. Section 6 — Trust, Boundaries, and Close

**H2:** Aggregated intelligence, not surveillance.

| Trust row | Required copy direction |
|-----------|-------------------------|
| No Patient Surveillance | ZoikoSignal™ does not track or expose individual patient behavior. |
| No Pharmacy Exposure | ZoikoSignal™ does not identify, rank, or expose individual pharmacies or their inventory. |
| No Exact Stock | ZoikoSignal™ expresses pressure and movement, never exact stock. |
| No Clinical Advice | ZoikoSignal™ does not recommend medicines, substitutions, or clinical actions. |
| K-Anonymity Governed | Outputs below threshold are suppressed; the applied threshold is disclosed. |
| Jurisdiction-Aware & Contract-Scoped | Coverage and outputs depend on jurisdiction, data availability, and contract. |

**Close strip** — H3: Act on medicine access pressure with governed intelligence. · Subheadline:
Use ZoikoSignal™ to understand demand movement, shortage pressure, and unmet demand across
medicines and regions — anonymized and k-anonymity-governed. · Primary CTA: Request ZoikoSignal™
Intelligence Briefing · Secondary CTA: View Intelligence Capabilities.

## 11. Contextual States

| State | Behavior |
|-------|----------|
| Public visitor | Show public page with Request Intelligence Briefing as dominant CTA. |
| Analyst-intent visitor | Prioritize Request Sample Report and Dashboard Access. |
| API-intent visitor | Route to ZoikoAvail™ API. |
| Medicine-identity visitor | Route to MediBase™. |
| Government/public-health visitor | Route to Government & Public Health with jurisdiction-aware language. |
| Patient/caregiver visitor | Route to Search Medicines. Do not push into licensing forms. |

## 12–18. Requirements Summary

- **Product/workflow:** minimum inquiry object (email, name, org, org type, primary interest,
  source, created date, queue, status); product surfaces include aggregated dashboards, report
  library, export center, and licensed data feeds. Do not collect PHI, patient identifiers, raw
  per-user search data, exact stock, or confidential pharmacy inventory in public forms.
- **Security/privacy/governance:** k-anonymity enforcement, aggregation/bucketing, audit logging,
  role/organization-scoped access, no public indexing of authenticated surfaces, versioned
  aggregation logic and thresholds.
- **Accessibility:** WCAG 2.2 AA; all charts have text equivalents and accessible summaries;
  status never by color alone; 44px+ touch targets; reduced-motion support.
- **Schema:** WebPage, Organization, BreadcrumbList, FAQPage (if approved). Avoid MedicalWebPage,
  Drug, Dataset unless legally approved.
- **Analytics:** funnel = arrival → capability/governance engagement → intent
  (briefing/report/dashboard/licensing) → conversion; same privacy guardrail as other pages.
- **Legal/trust copy:** ZoikoSignal™ provides aggregated, anonymized, k-anonymity-governed
  intelligence; it does not surveil patients, expose pharmacies or exact stock, provide clinical
  advice, or serve as a regulatory shortage register.
- **Acceptance criteria:** positions ZoikoSignal™ as governed anonymized intelligence; one
  dominant CTA; explains k-anonymity; avoids patient/pharmacy/exact-stock exposure; supports
  SEO/AEO; meets WCAG 2.2 AA; handoff-ready.

**Final recommendation:** Build ZoikoSignal™ as the intelligence product page under Enterprise &
Intelligence. Promise: Read access pressure. Expose no one. The correct next footer wireframe is
Enterprise Solutions.

---

# PART 4: Enterprise Solutions Page — Tier-0 Wireframe Specification

**ZOIKOMEDS · Enterprise Solutions Page · Detailed Wireframe Specification | Final**
**Footer Category:** Solutions · **Footer Link:** Enterprise Solutions
**Recommended URL:** `/enterprise` or `/solutions/enterprise`

## 1. Page Doctrine

The Enterprise Solutions page is the top-of-funnel commercial page for ZoikoMeds' governed
intelligence stack. It frames the three products — **MediBase™** (medicine identity),
**ZoikoAvail™** (availability confidence API), and **ZoikoSignal™** (anonymized intelligence) —
as one governed stack and routes each buyer to the right product page. It is not a product-detail
page, not a pricing page, and not a developer surface.

**Core question:** How do the ZoikoMeds products fit together, and which one solves my
organization's medicine-availability problem?

## 2. Strategic Role

| Item | Specification |
|------|---------------|
| Footer category | Solutions |
| Recommended URL | `/enterprise` |
| Page type | Commercial overview / router page |
| Primary audience | Executives, product and data leaders, procurement, market access, and integration teams across manufacturers, distributors, payers, health systems, pharmacy groups, and public sector. |
| Primary goal | Route qualified buyers into the correct product (MediBase™, ZoikoAvail™, ZoikoSignal™) and into an enterprise briefing. |
| Primary CTA | Request an Enterprise Briefing |
| Secondary CTA | Explore the Intelligence Stack |
| Contextual CTAs | Explore MediBase™; Explore ZoikoAvail™ API; Explore ZoikoSignal™; Request Security Pack; View Governance. |

## 3. SEO and AEO Targeting

- **Meta title:** Enterprise Medicine Availability Infrastructure | ZoikoMeds Enterprise Solutions
- **Meta description:** ZoikoMeds' governed intelligence stack — MediBase™ medicine identity,
  ZoikoAvail™ availability API, and ZoikoSignal™ shortage intelligence — for enterprises and
  institutions.
- **Keywords:** medicine availability infrastructure · pharmaceutical data platform · medicine
  identity data · availability API · shortage intelligence · healthcare data solutions.
- **AEO:** What is the ZoikoMeds enterprise stack? · How do MediBase™, ZoikoAvail™, and
  ZoikoSignal™ relate? · Which product fits my use case? · How is enterprise access governed? · How
  do I request a briefing?

## 4. Page Architecture — Six Sections

| Section | Job |
|---------|-----|
| 1. Hero | Frame the governed intelligence stack and the enterprise briefing CTA. |
| 2. The Intelligence Stack | Show the three products as one governed system and their relationships. |
| 3. Use Cases | Map the stack to enterprise outcomes across buyer types. |
| 4. Procurement Readiness | Present security, compliance, and procurement posture. |
| 5. Security Overview | Summarize certifications, controls, and governance (link to Trust Center). |
| 6. Access and Close | Route to product pages, security pack, and briefing; close with conversion. |

## 5. Sections — Content Direction

**Hero** — Eyebrow: ENTERPRISE SOLUTIONS · H1: The ZoikoMeds intelligence stack. · Subheadline:
Three governed products — medicine identity, availability confidence, and anonymized access
intelligence — built on one privacy-first, jurisdiction-aware infrastructure. · Primary CTA:
Request an Enterprise Briefing.

**The Intelligence Stack** (H2: Enterprise Intelligence Stack) —

| Product | Role in the stack | Explore |
|---------|-------------------|---------|
| MediBase™ | Governed medicine identity & normalization (the substrate). | Explore MediBase™ |
| ZoikoAvail™ | Availability confidence API built on clean identity. | Explore ZoikoAvail™ API |
| ZoikoSignal™ | Aggregated, anonymized access & shortage intelligence. | Explore ZoikoSignal™ |

**Use Cases** (H2: Use Cases — "How enterprises operationalize the stack") — telehealth, payer,
provider/health-system, pharmacy group, manufacturer/distributor, and public-sector outcomes,
each linking to the relevant product page.

**Procurement Readiness** — MSA, data-use restrictions, SSO/MFA readiness, audit logging,
role-based access, jurisdiction-scoped entitlements, DPA availability.

**Security Overview** (H2: Security Overview — "Certifications and controls") — summarize controls
and link to the Trust Center / Security Pack; do not publish unapproved certification claims.

## 6. Contextual States, Requirements, and Close

- **Contextual states:** route API-intent → ZoikoAvail™; identity-intent → MediBase™;
  intelligence-intent → ZoikoSignal™; public-sector → Government & Public Health; provider →
  Health Systems; patient/caregiver → Search Medicines.
- **Product/workflow:** minimum enterprise inquiry object (email, name, org, org type, primary
  interest, use-case summary, source, created date, queue, status). Do not collect PHI, exact
  stock, or confidential procurement documents via public forms.
- **Security/privacy/governance:** no exact stock, no patient data, no clinical advice; contract-
  scoped and audit-logged enterprise access; noindex authenticated surfaces.
- **Accessibility:** WCAG 2.2 AA; descriptive CTAs; status never by color alone; 44px+ targets.
- **Schema:** WebPage, Organization, BreadcrumbList, FAQPage (if approved). Avoid MedicalWebPage,
  Offer/Product implying medicine commerce.
- **Analytics:** arrival → stack engagement → product-intent → briefing conversion; standard
  privacy guardrail.
- **Acceptance criteria:** presents the three products as one governed stack; one dominant CTA
  (Request an Enterprise Briefing); routes correctly to each product; presents procurement/security
  posture without unapproved claims; WCAG 2.2 AA; handoff-ready.

**Close strip** — H3: Build on governed medicine availability infrastructure. · Primary CTA:
Request an Enterprise Briefing · Secondary CTA: Explore the Intelligence Stack.

**Final recommendation:** Build Enterprise Solutions as the Solutions-tier router page. The
correct next Solutions footer wireframes are Government & Public Health and Health Systems.

---

# PART 5: Government & Public Health Page — Tier-0 Wireframe Specification

**ZOIKOMEDS · Government & Public Health Page · Detailed Wireframe Specification | Final**
**Footer Category:** Solutions · **Footer Link:** Government & Public Health
**Recommended URL:** `/solutions/government` or `/government`

## 1. Page Doctrine

The Government & Public Health page is the public-sector solutions page. It positions ZoikoMeds
as jurisdiction-aware access-risk monitoring and preparedness intelligence for governments,
public-health agencies, and NGOs — built on aggregated, anonymized signals. It is not a
surveillance system, not a patient registry, not a dispensing or enforcement tool, and not a
clinical system.

**Core question:** How can a public-sector body monitor medicine access risk, shortage pressure,
and preparedness across jurisdictions without collecting patient data or exposing individual
pharmacies?

## 2. Strategic Role

| Item | Specification |
|------|---------------|
| Footer category | Solutions |
| Recommended URL | `/solutions/government` |
| Page type | Public-sector solutions page |
| Primary audience | Health ministries, public-health agencies, regulators, emergency-preparedness bodies, regional health authorities, and NGOs. |
| Primary goal | Convert qualified public-sector bodies into governed intelligence briefings and program discussions. |
| Primary CTA | Request a Public-Health Briefing |
| Secondary CTA | View Access-Risk Capabilities |
| Contextual CTAs | Request Preparedness Overview; Discuss Data Residency; Explore ZoikoSignal™; View Governance. |

## 3. SEO and AEO Targeting

- **Meta title:** Government & Public Health Medicine Access Intelligence | ZoikoMeds
- **Meta description:** Jurisdiction-aware, anonymized medicine access-risk and preparedness
  intelligence for governments, public-health agencies, and NGOs — privacy-first and
  data-residency-aware.
- **Keywords:** medicine access-risk monitoring · drug shortage preparedness · public-health
  medicine intelligence · jurisdiction medicine data · anonymized shortage monitoring.
- **AEO:** What does ZoikoMeds offer government and public-health bodies? · Is it a surveillance or
  patient-registry tool? · How is data anonymized and kept jurisdictional? · How is data residency
  handled? · How do agencies request access?

## 4. Page Architecture — Sections

| Section | Job |
|---------|-----|
| 1. Hero | Position jurisdiction-aware access-risk monitoring and preparedness. |
| 2. Access-Risk & Preparedness Model | Show regional access-risk, shortage-pressure, and preparedness outputs. |
| 3. Public-Sector Use Cases | Map to monitoring, preparedness, and access-program outcomes. |
| 4. Privacy, Residency & Governance | De-risk surveillance, patient-data, and residency concerns. |
| 5. Access & Programs | Explain briefings, programs, and data-residency options. |
| 6. Trust & Close | De-risk and convert. |

## 5. Sections — Content Direction (grounded in the built page)

**Hero** — Eyebrow: SOLUTIONS · H1: Government & Public Health. · Subheadline: Jurisdiction-aware
access-risk monitoring and preparedness intelligence — aggregated, anonymized, and
data-residency-aware. · Primary CTA: Request a Public-Health Briefing.

**Model / dashboards** — Regional Access Risk · Preparedness Index (national preparedness score) ·
Shortage Pressure (aggregate shortage-pressure index vs baseline) · Preparedness by Region
(preparedness index per macro-region). All outputs aggregated and k-anonymity-governed.

**Jurisdiction & Privacy** — Jurisdiction Overview · Privacy Status (privacy and data-residency
posture) · Governance Indicators (policy and transparency posture).

## 6. Governance, Requirements, and Close

| Governance area | Required standard |
|-----------------|-------------------|
| No surveillance / no registry | No patient-level data, no individual tracking, no patient registry. |
| No pharmacy exposure / no exact stock | Individual pharmacies and exact stock are never exposed. |
| Anonymization | K-anonymity thresholds and aggregation applied before output. |
| Data residency | Jurisdiction-specific residency and access controls where required. |
| Jurisdiction-aware controls | Medicine categories, controlled-medicine handling, and visibility respect local law. |
| Auditability | Access and data use audit-logged; transparency posture surfaced. |

- **Product/workflow:** minimum public-sector inquiry object (agency, jurisdiction, contact, org
  type, primary interest, source, created date, queue, status). No PHI or patient identifiers in
  public forms.
- **Accessibility:** WCAG 2.2 AA; charts/maps have text equivalents and accessible summaries;
  status never by color alone; 44px+ targets.
- **Schema:** WebPage, GovernmentService (if approved), Organization, BreadcrumbList. Avoid
  MedicalWebPage/Drug unless approved.
- **Analytics:** arrival → model/governance engagement → intent (briefing/preparedness/residency)
  → conversion; strict privacy guardrail (no patient identifiers, exact locations, exact stock).
- **Legal/trust copy:** governed, anonymized, jurisdiction-aware access-risk intelligence; not a
  surveillance, registry, dispensing, enforcement, or clinical system.
- **Acceptance criteria:** positions jurisdiction-aware anonymized access-risk monitoring; one
  dominant CTA; explains anonymization and data residency; avoids surveillance/registry framing;
  WCAG 2.2 AA; handoff-ready.

**Close strip** — H3: Monitor medicine access risk without collecting patient data. · Primary CTA:
Request a Public-Health Briefing · Secondary CTA: View Access-Risk Capabilities.

**Final recommendation:** Build Government & Public Health as a Solutions-tier page grounded in the
ZoikoSignal™ anonymization model. The correct next Solutions footer wireframe is Health Systems.

---

# PART 6: Health Systems Page — Tier-0 Wireframe Specification

**ZOIKOMEDS · Health Systems Page · Detailed Wireframe Specification | Final**
**Footer Category:** Solutions · **Footer Link:** Health Systems
**Recommended URL:** `/solutions/health-systems` or `/health-systems`

## 1. Page Doctrine

The Health Systems page is the provider-sector solutions page. It positions ZoikoMeds as
availability intelligence embedded in care navigation, discharge, and patient-access workflows —
governed, confidence-based, and non-clinical. It is not an EHR, not a clinical decision-support
system, not a prescribing or dispensing tool, and not an exact-stock feed.

**Core question:** How can a health system reduce medicine-access friction in discharge and care
navigation without taking on clinical, dispensing, or exact-stock risk?

## 2. Strategic Role

| Item | Specification |
|------|---------------|
| Footer category | Solutions |
| Recommended URL | `/solutions/health-systems` |
| Page type | Provider-sector solutions page |
| Primary audience | Health-system leaders, care-navigation and discharge teams, population-health and integration teams, pharmacy directors, and clinical informatics leaders. |
| Primary goal | Convert qualified health systems into workflow briefings and integration discussions. |
| Primary CTA | Request a Health-System Briefing |
| Secondary CTA | View Care-Navigation Capabilities |
| Contextual CTAs | Discuss Discharge Workflows; Request Integration Overview; Explore ZoikoAvail™ API; Explore ZoikoSignal™; View Governance. |

## 3. SEO and AEO Targeting

- **Meta title:** Medicine Availability Intelligence for Health Systems | ZoikoMeds
- **Meta description:** Governed, confidence-based medicine availability intelligence embedded in
  care navigation, discharge, and patient-access workflows — non-clinical and privacy-first.
- **Keywords:** medication access care navigation · discharge medication availability · patient
  access intelligence · health system medicine availability · care coordination pharmacy
  availability.
- **AEO:** What does ZoikoMeds offer health systems? · Is it clinical decision support or an EHR? ·
  How does it support discharge and care navigation? · Does it expose exact stock? · How is patient
  privacy protected? · How do health systems integrate it?

## 4. Page Architecture — Sections

| Section | Job |
|---------|-----|
| 1. Hero | Position availability intelligence embedded in care navigation. |
| 2. Care-Workflow Model | Show discharge support, care navigation, and availability guidance. |
| 3. Provider Use Cases | Map to discharge, care coordination, and patient-access outcomes. |
| 4. Clinical Boundaries & Governance | De-risk clinical, dispensing, and exact-stock concerns. |
| 5. Integration | Explain connection to clinical/data systems via ZoikoAvail™ API. |
| 6. Trust & Close | De-risk and convert. |

## 5. Sections — Content Direction (grounded in the built page)

**Hero** — Eyebrow: SOLUTIONS · H1: Health Systems. · Subheadline: Availability intelligence
embedded in care navigation — governed, confidence-based, and non-clinical. · Primary CTA: Request
a Health-System Briefing.

**Model / dashboards** — Patient Access Trends (access continuity, guidance acceptance) · Discharge
Support (coverage of discharge workflows) · Care Navigation (guidance surfaced to navigation
teams) · Availability Guidance (governed guidance principles) · Integration Status (connected
clinical and data systems).

## 6. Governance, Requirements, and Close

| Governance area | Required standard |
|-----------------|-------------------|
| No clinical advice | Guidance is availability-oriented; it does not recommend medicines, doses, substitutions, or treatments. |
| No dispensing / no prescription validation | Does not confirm eligibility, validate prescriptions, or approve dispensing. |
| No exact stock | Confidence-based availability only; exact stock is suppressed. |
| Patient privacy | Minimize/avoid PHI; any PHI-linked workflow is separately governed. |
| Confidence-based guidance | Guidance reflects availability confidence and freshness, and prompts direct confirmation when needed. |
| Integration governance | Clinical/data integration is contract-scoped, authenticated, and audit-logged (via ZoikoAvail™ API). |

- **Product/workflow:** minimum inquiry object (health system, contact, role, primary interest,
  use-case summary, source, created date, queue, status). No PHI in public forms.
- **Accessibility:** WCAG 2.2 AA; charts have text equivalents and accessible summaries; status
  never by color alone; 44px+ targets.
- **Schema:** WebPage, Organization, BreadcrumbList, FAQPage (if approved). Avoid MedicalWebPage,
  Drug, MedicalBusiness unless approved.
- **Analytics:** arrival → workflow/governance engagement → intent (briefing/discharge/integration)
  → conversion; standard privacy guardrail.
- **Legal/trust copy:** governed, confidence-based, non-clinical availability intelligence for care
  navigation; not an EHR, clinical decision-support, prescribing, dispensing, or exact-stock tool.
- **Acceptance criteria:** positions non-clinical availability intelligence in care workflows; one
  dominant CTA; explains discharge/care-navigation value; avoids clinical/dispensing/exact-stock
  claims; WCAG 2.2 AA; handoff-ready.

**Close strip** — H3: Reduce medicine-access friction in care navigation. · Primary CTA: Request a
Health-System Briefing · Secondary CTA: View Care-Navigation Capabilities.

**Final recommendation:** Build Health Systems as a Solutions-tier page grounded in ZoikoAvail™
confidence signals and ZoikoSignal™ access intelligence, with clear non-clinical boundaries.

---

# Appendix A: Backend-Relevant Contract Extractions

Cross-referenced, backend-relevant contracts embedded in the six wireframes above. These are the
data-model, API-boundary, workflow-object, and governance rules engineering can act on directly.

| Source page | Data-model / entities | API / capability boundary | Workflow objects | Security & governance rules |
|-------------|----------------------|---------------------------|------------------|-----------------------------|
| MediBase™ (Part 1) | Canonical medicine entity; product/presentation; identifier mapping (NDC, RxNorm/RxCUI, GTIN/GS1, DIN, dm+d, ATC, EAN/UPC, local); jurisdictional context; availability linkage; intelligence alignment. | Medicine identity lookup & matching; identifier mapping; data dictionary; bulk/licensed export; sandbox. | Inquiry object; mapping review queue; suppression/review-state states (verified, partner-supplied, needs-review, deprecated, suppressed). | Versioned schemas & mappings; provenance/license metadata; controlled-medicine suppression; RBAC/SSO/MFA; audit logging; no patient data; no exact stock. |
| ZoikoAvail™ API (Part 2) | Availability confidence signal object; freshness/signal metadata; pharmacy-participation context; jurisdiction fields. | Availability confidence; freshness metadata; medicine match (via MediBase™); confirmation pathways; location-aware workflows; event/webhook patterns. | API inquiry object; evaluation stages (interest→qualification→security→sandbox→implementation→production). | Exact-stock suppression; no clinical advice / no dispensing; PHI protection; pharmacy confidentiality; jurisdiction-aware controls; controlled-medicine safeguards; credential rotation/scoping; rate limits; audit logs. |
| ZoikoSignal™ (Part 3) | Aggregated signal cells (search, zero-result, restock, confirmation) by period & bucket; MediBase™-aligned medicine identity; regional aggregates. | Intelligence summary; aggregated cells; export (CSV); dashboard access; licensed data feed. | Inquiry object; report/dashboard/licensing paths; time & bucket filters. | K-anonymity thresholds (disclosed); aggregation/bucketing; no patient-level output; no individual pharmacy exposure; no exact stock; versioned aggregation logic; audit logging; jurisdiction-aware. |
| Enterprise (Part 4) | Enterprise inquiry object; product-routing metadata. | Router to MediBase™ / ZoikoAvail™ / ZoikoSignal™; briefing intake. | Enterprise inquiry object; use-case summary; queue/status. | MSA & data-use restrictions; SSO/MFA; RBAC; jurisdiction-scoped entitlements; audit logging; noindex authenticated surfaces. |
| Government & Public Health (Part 5) | Regional access-risk aggregates; preparedness index; shortage-pressure vs baseline; jurisdiction overview. | Access-risk/preparedness views; program intake; data-residency options. | Public-sector inquiry object; program discussions. | No surveillance/registry; no pharmacy exposure; no exact stock; k-anonymity; data residency; jurisdiction-aware controls; audit logging; transparency posture. |
| Health Systems (Part 6) | Patient-access trend aggregates (access continuity, guidance acceptance); discharge/care-navigation coverage; integration status. | Care-navigation availability guidance; discharge support; integration via ZoikoAvail™ API. | Health-system inquiry object; workflow/integration discussions. | No clinical advice; no dispensing/prescription validation; no exact stock; PHI minimization; confidence-based guidance; contract-scoped, authenticated, audit-logged integration. |

**Cross-cutting invariants (all pages):** no exact public pharmacy stock · no clinical advice /
prescribing / substitution / dispensing / eligibility · no patient identifiers / PHI by default ·
jurisdiction-aware controls on identity, identifiers, and visibility · enterprise access is
contract-scoped and audit-logged · WCAG 2.2 AA.

---

> **Provenance note:** Parts 0–2 (through §16) are a faithful transcription of the source material
> pasted into the build session. The tail of Part 2 (§16–§18) and Parts 3–6 plus Appendix A were
> authored to complete the reference in the same Tier-0 wireframe format, grounded in the ZoikoMeds
> governance doctrine established in Parts 0–2 and in the already-implemented pages
> (`frontend/src/pages/{MediBase,ZoikoAvail,ZoikoSignal,Enterprise,Government,HealthSystems}.jsx`).
> If canonical source text for Parts 3–6 later becomes available, reconcile these sections against it.
